Eli Lilly said its weight-loss drug Zepbound outperformed rival Novo Nordisk’s Wegovy in the first head-to-head trial of the two blockbusters. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke to Bloomberg TV about the results https://trib.al/Y3suGBA
Author: Bloomberg Television
Go to Source
News post in December 5, 2024, 12:05 am.
Visit Our Sponsor’s:
News Post In – News
